GUJINJEC share price, P/E, ROE & financials

Gujarat Inject (Kerala) (BSE: GUJINJEC) had a P/E of 49.1× on 6 Nov 2026, in line with the industry P/E of 49.1×, and the shares are 28% below their 52-week high. It earns ROCE of 21% and ROE of 17%. It is a small-cap company with a market cap of ₹15 Cr, ranked 20th of 20 Biotechnology companies by market cap; the shares rose 344% over the past year.

As of 6 Nov 2026Prices are delayed about 15 minutes; fundamentals are from the quarter ended Jun 2026.How we calculate this

past year

Open: ₹10.60
Day high: ₹10.99
Day low: ₹10.32
Prev. close: ₹10.86
Volume: 4.9 L

Health check

4 good · 2 fair

ReturnsAhead
+344.2% over a year, better than 7 of 7 peers.
Price tagIn line
P/E 49.1 vs industry 49.1.
GrowthStrong
Sales +493.2%, profit +253.5% a year over 3 years.
ProfitabilityStrong
ROCE 21.2% vs peer median 16.7%.
Balance sheetFair
Piotroski 4 of 9.
Red flagsNone found
No warning signs in the headline numbers.

Compared with 7 industry peers. Computed from reported figures. Educational, not a recommendation.

Biotechnology

19 listed peers. Screen the industry

Small cap

₹15 Cr, #20 of 20 in its industry by size.

Market sensitivity

Measuring against the NIFTY 50…

Key metrics

Last 12 months to Jun 2026: sales ₹47 Cr · profit ₹3 Cr

Market cap: ₹15 Cr; Small cap
P/E: 49.1; Industry 49.1
Price to book: 12.77; Peers 4.68
Dividend yield: 0.00%
ROE: 16.6%; Peers 14.3%
ROCE: 21.2%; Peers 16.7%
Debt to equity: n/a; Debt ₹0.00 Cr
EPS (TTM): ₹0.21
OPM (TTM): 8.4%; Net margin 6.4%
Sales growth: +414.4%; Latest quarter vs a year ago
Profit growth: +1602.9%; Latest quarter vs a year ago
Price to sales: 0.32

Strengths

Return on capital employed of 21.2%.
Quarterly profit up 1602.9% on a year ago.
Quarterly sales up 414.4% on a year ago.

No obvious red flags in the headline numbers.

Derived automatically from reported figures. Not a recommendation.

About Gujarat Inject (Kerala)

Gujarat Inject (Kerala) Limited engages in the business of trading of goods. The company was incorporated in 1991 and is based in Vadodara, India.

Headquarters: Vadodara
Employees: 4
Sector: Healthcare
ISIN: INE659F01022
Website: gujaratinject.com

Price range

52 weeks

₹2.37₹14.30

Today

₹10.32₹10.99

Avg volume (3M): 5 L
1-year return: plus 344.2%
From 52-week high: minus 27.8%

Peers · Biotechnology

Compare with peers Screen the whole industry

Company
BIOCONBiocon	365.10	plus 0.86%	59,794	122.5	1.73	2.8%	1.0%	19.4%	15.3%	−5.9%	0.14%	minus 4.9%
ANTHEMAnthem Biosciences	915.55	plus 0.22%	51,594	84.6	15.74	26.8%	20.4%	41.4%	26.2%	15.4%	0.22%	plus 30.1%
ONESOURCEOnesource Specialty Pharma	1,599.80	plus 1.13%	18,346	–	3.10	0.3%	0.0%	23.5%	232.3%	–	0.00%	minus 13.7%
CONCORDBIOConcord Biotech	632.60	minus 5.96%	13,236	47.4	6.48	16.7%	14.3%	34.5%	8.0%	2.8%	0.60%	minus 7.5%
BLUEJETBlue Jet Healthcare	553.80	minus 3.91%	9,607	34.5	4.52	24.0%	19.9%	31.4%	9.4%	15.7%	0.22%	minus 5.0%
SUPRIYASupriya Lifescience	695.80	minus 19.99%	5,600	28.2	4.68	22.3%	19.1%	21.4%	21.2%	32.5%	0.14%	plus 9.2%
ZOTAZota Health Care	1,231.10	plus 1.01%	4,264	–	6.82	−7.3%	−24.1%	0.1%	56.7%	–	0.08%	minus 21.9%
GUJINJECGujarat Inject (Kerala)	10.32	minus 4.97%	15	49.1	12.77	21.2%	16.6%	8.4%	493.2%	253.5%	0.00%	plus 344.2%
Median of 7 peers	–	0.22%	13,236	47.4	4.68	16.7%	14.3%	23.5%	21.2%	15.4%	0.14%	−5.0%

Quarterly results

Consolidated, ₹ crore

SalesSelect a row below to chart it

Jun 25	Sep 25	Dec 25	Mar 26	Jun 26
2.4	1.6	1.6	30.7	12.5
2.3	1.5	1.7	28.4	10.8
0.1	0	−0.1	2.3	1.7
4.1%	2.1%	−5.7%	7.4%	13.6%
0	0.1	0.1	0	0
–	0	–	0	–
0.1	0.1	0.1	2.3	1.7
25.2%	25.0%	25.2%	27.8%	25.8%
0.1	0.1	0	1.6	1.3
0.01	0.01	0.00	0.11	0.09

Profit & loss

Yearly, ₹ crore

Sales CAGR 3Y: +493.2%
Profit CAGR 3Y: +253.5%
EPS CAGR 3Y: +191.5%
ROE: 16.6%

Net profitSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
0.2	5.8	19	36.3
–	+3231.1%	+229.0%	+90.7%
0.5	5.7	18	34
−0.4	0	1.1	2.3
−216.1%	0.8%	5.6%	6.4%
0.4	0.1	0.2	0.2
–	0	0	0
−0	–	–	–
0.1	0.1	1.3	2.5
26.0%	21.4%	18.9%	27.6%
0	0.1	1	1.8
–	+101.6%	+1129.1%	+78.3%
0.01	0.01	0.07	0.12

Forecast

Your assumptions, not a prediction

Balance sheet

At each financial year end, ₹ crore

Total assetsSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
4.9	11.3	14.6	14.6
−5.7	−2.7	−4.6	−2.8
0.6	–	–	–
0.5	0.1	1.9	24.8
0.3	8.7	12	36.7
–	–	–	20.8
–	–	–	20.8
–	–	–	0
0.1	2.9	0	0.7
0.2	5.8	11.9	−5.5
0.3	8.7	12	36.7

Cash flow

Yearly, ₹ crore

Cash from operationsSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
0.1	−6	−3.5	21.2
0	0	0.2	−20.6
–	8.9	0.5	–
0.1	2.9	−2.9	0.7
–	–	–	−20.8
0.1	−6	−3.5	0.5

Shareholding pattern

This company is listed only on BSE, so there’s no NSE category split. See Major shareholders below for the named holders.

Major shareholders

BSE filing

Filings & events

News

No recent news coverage found.

My notes

Private to you